When will Yeztugo be available?

Gilead has not announced a launch date yet, as the drug is still under FDA review.

How is Yeztugo different from other PrEP drugs?

Yeztugo is the first weekly oral option, while most current PrEP drugs require daily dosing or are long-acting injectables.

What is the ticker for Gilead Sciences?

Gilead Sciences trades on Nasdaq under the ticker GILD.

FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention

Gilead Sciences announced that the FDA has accepted its filing for Yeztugo, a once-weekly oral drug for HIV prevention. The drug aims to provide a new long-acting PrEP option.

June 16, 2026

2 min read

Source: Zacks

Gilead Sciences (ticker: GILD) announced that the U.S. Food and Drug Administration (FDA) has accepted its filing for Yeztugo, a once-weekly oral drug for HIV prevention. The drug aims to provide a new long-acting pre-exposure prophylaxis (PrEP) option, potentially expanding access to prevention.

The Product

Yeztugo is a once-weekly oral drug for HIV prevention, designed as a long-acting alternative to current daily options. It works by inhibiting viral replication.

Pricing and Availability

Gilead has not yet disclosed the price or potential launch date for Yeztugo. The FDA is expected to set a review date in the coming months.

Competition

Yeztugo will compete with existing PrEP options such as Gilead's own Truvada and Descovy, as well as ViiV Healthcare's Apretude (a long-acting injectable). If approved, it would be the first weekly oral option for HIV prevention.

Potential Impact on the Company

Yeztugo could strengthen Gilead's position in the HIV prevention market, particularly if it attracts patients preferring less frequent dosing. However, it may face strong competition from long-acting injectables.

Frequently Asked Questions

Yeztugo is a once-weekly oral drug for HIV prevention developed by Gilead Sciences.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.